SAFETY DATA SHEET



1. Identification

Product identifier Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg

Other means of identification

Synonyms SIMPLICEF® * Cefpodoxime Proxetil Tablets

Recommended use Veterinary product used as antibiotic agent

Recommended restrictions Not for human use

Manufacturer/Importer/Supplier/Distributor information

Company Name (USA) Zoetis Inc.

10 Sylvan Way

Parsippany, New Jersey 07054 (USA)

Rocky Mountain Poison &

Drug Safety

1-866-531-8896

Product Support/Technical

1-888-963-8471

Services

Emergency telephone

numbers

CHEMTREC (24 hours): 1-800-424-9300

International CHEMTREC (24 hours): +1-703-527-3887

Company Name (CA) Zoetis Canada Inc.

16740 Trans-Canada Highway Kirkland, Quebec, H9H 4M7

Emergency telephone

number

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail productsupport@zoetis.com

Product Support 1-800-461-0917

All Safety Data Sheets are available via our Zoetis Canada website at

https://www.zoetis.ca/sds/sds.aspx

Supplier Not available.

2. Hazard identification

Physical hazards Not classified.

Health hazards Sensitization, respiratory Category 1

Sensitization, skin Category 1

Environmental hazards Not classified.

Label elements



Signal word Danger

Hazard statement May cause an allergic skin reaction. May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

Precautionary statement

Prevention Avoid breathing dust/fume/gas/mist/vapours/spray. Contaminated work clothing should not be

allowed out of the workplace. Wear protective gloves. Wear respiratory protection.

Response IF ON SKIN: Wash with plenty of water. IF INHALED: Remove person to fresh air and keep

comfortable for breathing. If skin irritation or rash occurs: Get medical advice/attention. If experiencing respiratory symptoms: Call a POISON CENTRE/doctor. Take off contaminated

clothing and wash it before reuse.

Storage Store away from incompatible materials.

Dispose of contents/container in accordance with local/regional/national/international regulations. **Disposal**

Supplemental information

Other hazards

None known.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Magnesium Stearate		557-04-0	<1
Cefpodoxime Proxetil		87239-81-4	100 or 200 mg/tablet

All concentrations are in percent by weight unless ingredient is a gas. Gas concentrations are in percent by volume.

4. First-aid measures

Inhalation If experiencing respiratory symptoms: Call a POISON CENTRE or doctor/physician.

Skin contact Remove contaminated clothing immediately and wash skin with soap and water. In case of

eczema or other skin disorders: Seek medical attention and take along these instructions. Wash

contaminated clothing before reuse.

Immediately flush eyes with plenty of water for at least 15 minutes. Remove contact lenses, if Eve contact

present and easy to do. Continue rinsing. Get medical attention if irritation develops and persists.

Rinse mouth. Never give anything by mouth to a victim who is unconscious or is having Ingestion

convulsions. Do not induce vomiting without advice from poison control center. Get medical

advice/attention if you feel unwell.

anaphylaxis upon exposure to this drug.

Most important

symptoms/effects, acute and

delayed

Direct contact with eyes may cause temporary irritation. Exposed individuals may experience eye tearing, redness, and discomfort. Mild skin irritation. May cause an allergic skin reaction. May cause allergic respiratory reaction. Dermatitis. Rash. Difficulty in breathing. May cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation,

vomiting, transient diarrhea, nausea, and abdominal pain.

Indication of immediate medical attention and special

treatment needed

General information

Provide general supportive measures and treat symptomatically. Keep victim under observation. Symptoms may be delayed. Individuals who are sensitive to beta lactam antibiotics, both penicillins and cephalosporins, may experience contact or systemic hypersensitivity and

IF exposed or concerned: Get medical advice/attention. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Wash contaminated

clothing before reuse. For personal protection, see section 8 of the SDS.

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing

media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

equipment/instructions

Use water spray to cool unopened containers.

Specific methods

General fire hazards

Use standard firefighting procedures and consider the hazards of other involved materials.

No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. Wear appropriate protective equipment and clothing during clean-up. Avoid the generation of dusts during clean-up. Avoid inhalation of dust. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. Avoid contact with eyes, skin, and clothing. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up

Ensure adequate ventilation. Remove sources of ignition.

Large Spills: Stop the flow of material, if this is without risk. Absorb in vermiculite, dry sand or earth and place into containers. Clean surface thoroughly to remove residual contamination.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills in original containers for re-use. For waste disposal, see section 13 of the SDS. Avoid discharge into drains, water courses or onto the ground.

Environmental precautions

7. Handling and storage

Precautions for safe handling

Minimise dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes. Avoid contact with eyes, skin, and clothing. Avoid prolonged exposure. When using, do not eat, drink or smoke. Wear appropriate personal protective equipment. Wash thoroughly after handling. Avoid release to the environment.

Conditions for safe storage, including any incompatibilities

Keep away from heat and sources of ignition. Store in original tightly closed container. Store in a well-ventilated place. Keep out of the reach of children. Store away from incompatible materials (see Section 10 of the SDS). Store at 15 - 25°C (59 - 77°F).

8. Exposure controls/personal protection

Occupational exposure limits

Zoetis Components	Туре	Value	
Cefpodoxime Proxetil (CAS 87239-81-4)	TWA	100 μg/m3	
US. ACGIH Threshold Limit Value	s (TLV)		
Components	Туре	Value	Form
Magnesium Stearate (CAS 557-04-0)	TWA	3 mg/m3	Respirable fraction.
		10 mg/m3	Inhalable fraction.
Canada. Alberta OELs (Occupatio	nal Health & Safety Code, Sc	hedule 1, Table 2), as amende	ed
Components	Туре	Value	
Magnesium Stearate (CAS 557-04-0)	TWA	10 mg/m3	
Canada. British Columbia OELs. (Safety Regulation 296/97, as ame		ts for Chemical Substances, (Occupational Health and
Components	Туре	Value	Form
Magnesium Stearate (CAS 557-04-0)	TWA	3 mg/m3	Respirable.
		10 mg/m3	Inhalable
Canada. Manitoba OELs (Reg. 217	7/2006, The Workplace Safety	And Health Act), as amended	i
Components	Туре	Value	Form
Magnesium Stearate (CAS 557-04-0)	TWA	3 mg/m3	Respirable fraction.
		10 mg/m3	Inhalable fraction.
Canada. New Brunswick OELs: TI Publication (New Brunswick Regu		Based on the 1991 and 1997	ACGIH TLVs and BEIs
Components	Type	Value	
Magnesium Stearate (CAS 557-04-0)	TWA	10 mg/m3	
Canada. Ontario OELs. (Control o	f Exposure to Biological or C	hemical Agents), as amended	i
Components	Туре	Value	Form
Magnesium Stearate (CAS 557-04-0)	TWA	3 mg/m3	Respirable fraction.

Canada. Quebec OELs. (Ministry of Labor - Regulation respecting occupational health and safety), as amended Components Value Type

Magnesium Stearate (CAS TWA 10 ppm

557-04-0)

Canada. Saskatchewan OELs (Occupational Health and Safety Regulations, 1996, Table 21), as amended

Components Value

15 minute

Magnesium Stearate (CAS 557-04-0)

Biological limit values No biological exposure limits noted for the ingredient(s).

OEL Additional Information: Sensitizer **Exposure guidelines**

Not available. Control banding approach

Appropriate engineering

controls

Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. Ensure

20 mg/m3

Individual protection measures, such as personal protective equipment

If contact is likely, safety glasses with side shields are recommended. Eye/face protection

Skin protection

Wear impervious gloves if skin contact is possible. Hand protection

Other Wear suitable protective clothing. Use protective clothing (uniforms, lab coats, disposable

coveralls, etc.) in both production and laboratory areas.

adequate ventilation, especially in confined areas.

No personal respiratory protective equipment normally required. If the applicable Occupational Respiratory protection

Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient

to control exposures to below the OEL.

Not applicable. Thermal hazards

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. Contaminated work clothing should not be allowed out of the workplace.

9. Physical and chemical properties

Appearance Tablets. Solid. Physical state Solid. **Form**

> Colour Red-orange (100 mg). Light orange. (200 mg).

Odour Not available. **Odour threshold** Not available. pН Not available. Not available. Melting point/freezing point Initial boiling point and boiling Not available.

range

Flash point Not available. Not available. **Evaporation rate** Not available. Flammability (solid, gas) Upper/lower flammability or explosive limits

Explosive limit - lower (%) Not available. Explosive limit - upper

(%)

Not available.

Not available. Vapour pressure Not available. Vapour density Not available. Relative density

Solubility(ies)

Not available. Solubility (water)

Partition coefficient (n-octanol/water)

Not available.

Auto-ignition temperatureNot available.Decomposition temperatureNot available.ViscosityNot available.

Other information

Explosive properties Not explosive. **Oxidising properties** Not oxidising.

10. Stability and reactivity

ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

Conditions to avoid

reactions

No dangerous reaction known under conditions of normal use.

Heat, flames and sparks. Contact with incompatible materials.

Incompatible materials Strong oxidising agents.

Hazardous decomposition

products

Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

11. Toxicological information

Information on likely routes of exposure

Inhalation May cause allergy or asthma symptoms or breathing difficulties if inhaled. Prolonged

inhalation may be harmful.

Skin contact May cause an allergic skin reaction.

Cefpodoxime Proxetil Species: Rabbit

Severity: No effect

Eye contact Direct contact with eyes may cause temporary irritation.

Cefpodoxime Proxetil Species: Rabbit Severity: Minimal

Ingestion may result in mild gastrointestinal irritation with nausea, vomiting, or diarrhea.

However, ingestion is not likely to be a primary route of occupational exposure.

Symptoms related to the physical, chemical and toxicological characteristics

Ingestion

Direct contact with eyes may cause temporary irritation. Exposed individuals may experience eye tearing, redness, and discomfort. Mild skin irritation. May cause an allergic skin reaction. Dermatitis. Rash. Difficulty in breathing. May cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation.

vomiting, transient diarrhea, nausea, and abdominal pain.

Information on toxicological effects

Acute toxicity Expected to be a low hazard for usual industrial or commercial handling by trained

personnel. Individuals sensitive to this material or other materials in its chemical class

may develop allergic reactions.

Components Species Test Results

Cefpodoxime Proxetil (CAS 87239-81-4)

Acute

Intravenous

LD50 Rat > 4000 mg/kg

Oral

LD50 Mouse > 8000 mg/kg

Other

LD50 Mouse 2535 mg/kg [Sub-tenon injection (eye)]

Subcutaneous

LD50 Mouse > 10000 mg/kg

Material name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg
Version #: 02 Revision date: 08-August-2023 Issue date: 26-May-2017

Components Species Test Results

Magnesium Stearate (CAS 557-04-0)

Chronic Oral

LOAEL Rat 1092 g/kg, 13 weeks Liver

Skin corrosion/irritation Prolonged skin contact may cause temporary irritation.

Corrosivity

Cefpodoxime Proxetil Species: Rabbit Severity: No effect

Serious eye damage/eye

irritation

Direct contact with eyes may cause temporary irritation.

Eye contact

Cefpodoxime Proxetil Species: Rabbit Severity: Minimal

Respiratory or skin sensitisation

Canada - Alberta OELs: Irritant

Magnesium Stearate (CAS 557-04-0) Irritant

Respiratory sensitisation May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Skin sensitisation May cause an allergic skin reaction.

Germ cell mutagenicityNo data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Mutagenicity

Cefpodoxime Proxetil Bacterial Mutagenicity (Ames)

Result: Negative Species: Salmonella

Chromosome Aberration

Result: Negative

In Vivo Micronucleus Result: Negative

Unscheduled DNA Synthesis

Result: Negative

Carcinogenicity This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.

ACGIH Carcinogens

Magnesium Stearate (CAS 557-04-0) A4 Not classifiable as a human carcinogen.

Canada - Manitoba OELs: carcinogenicity

Magnesium Stearate (CAS 557-04-0) Not classifiable as a human carcinogen.

Reproductive toxicity This product is not expected to cause reproductive or developmental effects.

Developmental effects

Cefpodoxime Proxetil 100 mg/kg/day Embryo / Fetal Development, Not

Teratogenic, Fetotoxicity

Result: NOAEL Species: Rat Organ: Oral

30 mg/kg/day Embryo / Fetal Development, Not Teratogenic,

Fetotoxicity Result: NOAEL Species: Rabbit Organ: Oral

Reproductivity

Cefpodoxime Proxetil > 500 mg/kg/day Reproductive & Fertility, Fertility

Result: NOAEL Species: Rabbit Organ: Oral Reproductivity
Cefpodoxime Proxetil

> 500 mg/kg/day Reproductive & Fertility, Fertility

Result: NOAEL Species: Rat Organ: Oral

Specific target organ toxicity -

single exposure

Not classified.

Specific target organ toxicity -

repeated exposure

Not classified.

Aspiration hazard

Not an aspiration hazard.

Chronic effects

Prolonged inhalation may be harmful.

Further information

Caution - Pharmaceutical agent. Individuals who are sensitive to beta lactam antibiotics,

both penicillins and cephalosporins, may experience contact or systemic

hypersensitivity and anaphylaxis upon exposure to this drug. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade

fever, bloody stools, and abdominal pain) may also occur.

12. Ecological information

Ecotoxicity

Avoid release to the environment. The product is not classified as environmentally hazardous. However, this does not exclude the possibility that large or frequent spills can have a harmful or damaging effect on the environment.

Persistence and degradability

No data is available on the degradability of this product.

Bioaccumulative potential Mobility in soil

No data available. No data available.

Other adverse effects

No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructions

Avoid release to the environment. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Dispose of contents/container in accordance with local/regional/national/international regulations.

Local disposal regulations

Hazardous waste code

Dispose in accordance with all applicable regulations.

The waste code should be assigned in discussion between the user, the producer and the waste

disposal company. None known.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner.

Contaminated packaging

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

TDG

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable.

15. Regulatory information

Canadian regulations

This product has been classified in accordance with the hazard criteria of the HPR and the SDS contains all the information required by the HPR.

Controlled Drugs and Substances Act

Not regulated.

Export Control List (CEPA 1999, Schedule 3)

Not listed.

Greenhouse Gases

Not listed.

Precursor Control Regulations

Not regulated.

International regulations

Stockholm Convention

Not applicable.

Rotterdam Convention

Not applicable.

Kyoto Protocol

Not applicable.

Montreal Protocol

Not applicable.

Basel Convention

Not applicable.

Country(s) or region

International Inventories

Australia

Taiwan

Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances	No

Australian Inventory of Industrial Chemicals (AICIS)

Taiwan Chemical Substance Inventory (TCSI)

16. Other information

Issue date 26-May-2017 **Revision date** 08-August-2023

Version No.

Disclaimer Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while

> it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently

available.

(PICCS)

Inventory name

Revision information This document has undergone significant changes and should be reviewed in its entirety.

Material name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg Version #: 02 Revision date: 08-August-2023 Issue date: 26-May-2017 On inventory (yes/no)*

No

No

United States & Puerto Rico Toxic Substances Control Act (TSCA) Inventory No *A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).